microRNA (miRNA)

microRNA (miRNA)

Global microRNA (miRNA) Market to Reach US$919.2 Million by 2030

The global market for microRNA (miRNA) estimated at US$346.2 Million in the year 2023, is expected to reach US$919.2 Million by 2030, growing at a CAGR of 15.0% over the analysis period 2023-2030. microRNA Products, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$453.7 Million by the end of the analysis period. Growth in the microRNA Services segment is estimated at 16.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$135.7 Million While China is Forecast to Grow at 18.7% CAGR

The microRNA (miRNA) market in the U.S. is estimated at US$135.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$99.9 Million by the year 2030 trailing a CAGR of 18.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.8% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

Global microRNA (miRNA) Market - Key Trends and Drivers Summarized

MicroRNAs (miRNAs) are a class of small, non-coding RNA molecules that play a crucial role in regulating gene expression at the post-transcriptional level. Typically about 22 nucleotides long, miRNAs bind to complementary sequences on target messenger RNA (mRNA) transcripts, usually resulting in gene silencing via translational repression or target degradation. The discovery of miRNAs has significantly advanced our understanding of how genes are regulated in cells and has implications for a wide range of biological processes including development, differentiation, and metabolism. Given their involvement in various cellular pathways, miRNAs are also considered vital in the pathology of numerous diseases, notably cancer, cardiovascular diseases, and neurodegenerative disorders.

Research into miRNAs has burgeoned, revealing their potential as biomarkers for disease diagnosis and prognosis, as well as targets for therapeutic intervention. Tools and technologies to study miRNAs have also evolved, ranging from advanced sequencing techniques to bioinformatics tools designed to predict miRNA targets and functions. In the clinical context, miRNA-based diagnostics have shown promise in identifying specific miRNAs associated with particular disease states, which can lead to early detection and more personalized treatment plans. Moreover, miRNA therapeutics, which aim to modulate the function of specific miRNAs, are in development, with several candidates in preclinical and clinical trials. These therapeutic strategies include miRNA mimics, which are synthetic miRNAs designed to restore normal function to cells, and miRNA inhibitors, which block the function of miRNAs involved in disease progression.

The growth in the miRNA market is driven by several factors, including advances in miRNA profiling technologies, increased investment in miRNA research and therapeutic development, and a growing awareness of the potential of miRNAs in precision medicine. Technological advancements have led to more efficient and cost-effective methods for detecting and quantifying miRNAs, enhancing their applicability in both research and clinical settings. The pharmaceutical and biotechnological sectors are increasingly focusing on developing miRNA-based therapeutics, attracted by their ability to target multiple aspects of disease pathways. Moreover, as the healthcare industry moves toward more personalized treatment options, the demand for miRNA diagnostics and therapeutics is expected to rise, reflecting their potential to tailor treatments to individual genetic profiles and disease conditions. This trend is bolstered by a growing body of research that links specific miRNAs to particular diseases, further underpinning the clinical value of miRNAs as both biomarkers and therapeutic targets.

Select Competitors (Total 64 Featured) -

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Abcam PLC
• BioVendor - Laboratorni medicina a.s
• GeneCopoeia, Inc.
• AKESOgen, Inc.
• Entos Pharmaceuticals
• Genomnia
• Guangzhou Ruibo Biotechnology Co., Ltd.
• 20Med Therapeutics
• AceRNA Technologies Co., Ltd.
• AptamiR Therapeutics
• Causeway Therapeutics
• Cardior Pharmaceuticals
• Craif

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.